Dysregulated immune proteins in plasma in the UK Biobank predict Multiple Myeloma 12 years before clinical diagnosis.
Fieggen J. et al, (2025), Blood adv
Constructing a Computational Workflow for the Identification of Novel Cellular and Molecular Drivers of Human Granulopoiesis
Riva SG. et al, (2024), Blood, 144, 2525 - 2525
KLF5 Is a Key Regulator of IMiD-Induced Neutropenia
Simoglou Karali C. et al, (2024), Blood, 144, 2527 - 2527
Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma.
Van Oekelen O. et al, (2024), Cell rep med, 5
Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma.
Amatangelo M. et al, (2024), Cell rep med
Multiple myeloma and its treatment contribute to increased platelet reactivity.
Mitchell JL. et al, (2023), Platelets, 34
Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase.
Jeyaraju DV. et al, (2023), Haematologica
Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent thalassemia
Thakurta A., (2023), American journal of hematology
Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trial.
Menezes DL. et al, (2023), Br j haematol, 201, 1129 - 1143
High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma.
Samur MK. et al, (2023), Blood, 141, 1724 - 1736
The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM.
Stong N. et al, (2023), Blood, 141, 1574 - 1583
Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma.
Ansari-Pour N. et al, (2023), Blood, 141, 620 - 633
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.
Kurata K. et al, (2023), Blood cancer j, 13
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.
Kurata K. et al, (2023), Blood cancer j, 13
Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma.
Gooding S. et al, (2022), Blood, 140, 1816 - 1821
Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.
Döhner H. et al, (2022), Blood, 140, 1674 - 1685
Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma.
Sudha P. et al, (2022), Clin cancer res, 28, 2854 - 2864
Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1.
Wu W. et al, (2022), Blood, 139, 2024 - 2037
The Next Frontier: Translational Development of Ubiquitination, SUMOylation, and NEDDylation in Cancer.
Pellegrino NE. et al, (2022), Int j mol sci, 23
Biomarker analysis to support dose optimization of iberdomide (IBER) as monotherapy and in combination with standard of care treatments for multiple myeloma from a phase 1/2 trial
Amatangelo M. et al, (2022), Clinical lymphoma myeloma & leukemia, 22, S162 - S162